Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Late stage ovarian cancer gene expression profiles

ABSTRACT: Gene expression profiling on 63 stage III-IV papillary serous ovarian cancer samples resected during primary debulking at the University of Turin, Italy. Only the primary ovarian mass and no metastases were included in this analysis. The study focused on ovarian cancer chemokine expressions

ORGANISM(S): Homo sapiens

PROVIDER: GSE62873 | GEO | 2014/12/04

SECONDARY ACCESSION(S): PRJNA265868

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Late stage ovarian cancer gene expression profiles

Project description:Gene expression profiling on 63 stage III-IV papillary serous ovarian cancer samples resected during primary debulking at the University of Turin, Italy. Only the primary ovarian mass and no metastases were included in this analysis. The study focused on ovarian cancer chemokine expressions Only the primary ovarian mass and no metastases were included in this analysis.

2014-10-31 | E-GEOD-62873 | biostudies-arrayexpress

Transcription profiling of human late-stage, high-grade papillary serous ovarian adenocarcinomas

Project description:To demonstrate the use of a whole-genome oligonucleotide array to perform expression profiling on a series of microdissected late-stage, high-grade papillary serous ovarian adenocarcinomas to establish a prognostic gene signature correlating with survival and to identify novel survival factors in ovarian cancer. Advanced stage papillary serous tumors of the ovary are responsible for the majority of ovarian cancer deaths, yet the molecular determinants modulating patient survival are poorly characterized. We identify and validate a prognostic gene expression signature correlating with survival in a series of microdissected serous ovarian tumors. Experiment Overall Design: We identified 53 advanced stage, high-grade primary tumor specimens and 10 normal ovarian surface epithelium (OSE) brushings.

2009-10-23 | E-GEOD-18520 | biostudies-arrayexpress

MiRNA profiles of high grade serous papillary ovarian cancer tumors and normal fallopian tube epithelium

Project description:Fallopian tube epithelium is the tissue-of-origin of most high grade serous papillary ovarian carcinoma. This tumor has been exensively investigated and sequenced but expression profiling data of normal fallopian tube epithelial cells is still rare. This project compares the miRNA profiles of high grade serous papillary ovarian tumors (FFPE and fresh frozen) to that of normal unmatched epithelial cells from resected fallopian tubes.

2019-12-31 | GSE131790 | GEO

Matched primary ovarian cancer, omental metastases, and non-omental metastases from 10 patients with high-grade serous ovarian carcinoma

Project description:Matched high-grade serous ovarian carcinoma samples collected from the ovary (ov), omental metastasis (om-met), and non-omental intraperitoneal metastasis (met) from 10 patients at the time of primary debulking surgery were analyzed for RNA expression by RNA sequencing.

2020-07-02 | GSE133296 | GEO

miRNA profiling of longitudinal ovarian cancer biopsies collected before and after platinum-based neo-adjuvant chemotherapy

Project description:In the last decades platinum-based neo-adjuvant chemotherapy (NACT) has been recognized as a reliable therapeutic strategy in patients with un-resectable advanced epithelial ovarian cancer (EOC). However, the molecular changes induced by NACT at miRNA level, and their prognostic role has not been clarified until now. In order to uncover miRNAs that are altered in EOC tumor which received NACT, we performed whole-miRNA analysis on 82 FIGO Stage IIIC-IV high-grade serous (HGS) tumors, whose samples had been collected at complete primary debulking (PDS) and at interval-debulking surgery (IDS) after fter 4 courses of NACT.

2016-01-20 | E-MTAB-3696 | biostudies-arrayexpress

Whole-genome oligonucleotide expression analysis of papillary serous ovarian adenocarcinomas

2009-10-17 | GSE18520 | GEO

Identification of a Potential Ovarian Cancer Stem Cell Gene Expression Profile from Advanced Stage Papillary Serous Ovarian Cancer

Project description:To identify the potential ovarian cancer stem cell gene expression profile from isolated side population of fresh ascites obtained from women with high-grade advanced stage papillary serous ovarian adenocarcinoma Microarrays were used to interrogate the differentially expressed genes between side population (SP) and main population (MP) isolated from fresh ascites obtained from women with high-grade advanced stage papillary serous ovarian adenocarcinoma, and the results were analyzed by paired T-test using BRB-ArrayTools

2011-11-23 | GSE33874 | GEO

Spatial transcriptomics reveals ovarian cancer subclones with different microenvironments

Project description:8 spatial RNA-seq experiments (10x Genomics Visium) and 5 single-cell RNA-seq experiments (10x Genomics Chromium) using high-grade serous ovarian carcinoma (HGSOC) samples obtained from the ovaries during the interval debulking surgery

2022-08-29 | GSE211956 | GEO

Identification of a Potential Ovarian Cancer Stem Cell Gene Expression Profile from Advanced Stage Papillary Serous Ovarian Cancer

2011-11-23 | E-GEOD-33874 | biostudies-arrayexpress

Molecular analysis of clinically defined subsets of high-grade serous ovarian cancer

Project description:The diversity and heterogeneity within high-grade serous ovarian cancer (HGSC) is not well understood. Comprehensive molecular analyses were performed including high-pass whole-genome sequencing, targeted deep DNA sequencing, RNA sequencing, reverse-phase protein arrays, mass spectrometry-based proteomics and phosphoproteomics, and immune profiling on primary and metastatic sites from highly clinically annotated HGSC samples. Samples were obtained pre-treatment based on a laparoscopic triage algorithm from patients who underwent R0 tumor debulking or received neoadjuvant chemotherapy (NACT) with excellent or poor response.

2020-05-27 | PXD014980 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data